Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study

Basit Öğe Kaydı
dc.authorid0000-0002-9782-6807
dc.authorid0000-0002-9614-0651
dc.authorid0000-0002-1976-3951
dc.authorid0000-0001-5528-7852
dc.authorid0000-0002-0853-4096
dc.contributor.authorBeypinar, Ismail
dc.contributor.authorDemir, Hacer
dc.contributor.authorYaslikaya, Sendag
dc.contributor.authorKoseci, Tolga
dc.contributor.authorDemir, Bilgin
dc.contributor.authorColak, Gokhan
dc.contributor.authorAgaoglu, Ahmet Burak
dc.date.accessioned2026-01-24T12:30:55Z
dc.date.available2026-01-24T12:30:55Z
dc.date.issued2024
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractPurpose In advanced breast cancer, endocrine therapy is preferred in the absence of visceral crisis. Cyclin-dependent kinase inhibitors (CDKi) are the gold standards. The selection of subsequent treatments after CDKi treatment is still controversial, and the efficacy of everolimus (EVE) combinations is unknown. In this study, we aimed to investigate the efficacy of EVE after CDKi administration in real-life experiences. Method The study received data from 208 patients from 26 cancer centers. Demographic and histologic features, diagnosis, progression, last visit dates, and toxicities were recorded. This study was a retrospective case series. Results One hundred and seven patients received palbociclib, while 101 patients received ribociclib as a CDKi. The overall response and disease control rates of EVE combinations were 60% and 88%, respectively. In univariate analysis, the absence of liver metastasis, age > 40 years, better type of response, and immediate treatment after CDKi were related to increased progression-free survival. Liver metastasis and response type were significantly associated with overall survival. In the multivariate analysis, response remained significant in terms of progression-free survival, while response type, liver metastatic disease, and hematologic toxicity were prognostic in terms of overall survival. Conclusion This study provides evidence of the benefits of EVE combinations after CDKi treatment. EVE combinations may be more appropriate for patients with non-liver metastasis, and the first treatment response shows the benefit of treatment. In addition, immediate treatment after CDKi treatment is more beneficial than later lines of treatment.
dc.identifier.doi10.1007/s10549-024-07456-x
dc.identifier.endpage604
dc.identifier.issn0167-6806
dc.identifier.issn1573-7217
dc.identifier.issue3
dc.identifier.pmid39123071
dc.identifier.startpage597
dc.identifier.urihttps://doi.org/10.1007/s10549-024-07456-x
dc.identifier.urihttps://hdl.handle.net/20.500.12868/5532
dc.identifier.volume208
dc.identifier.wosWOS:001288064700001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofBreast Cancer Research and Treatment
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260121
dc.subjectEverolimus
dc.subjectBreast cancer
dc.subjectCyclin-dependent Kinase Inhibitors
dc.subjectPalbociclib
dc.subjectRibociclib
dc.subjectLife experience
dc.titleEfficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu